The AMPLATZER Vascular Plug receives clearance from the US Food and Drug Administration for the use of the medical device as an implantable device. The medical device allows the treatment to close veins and arteries through a minimal invasive alternative to an array of common vascular procedures. The Plug allows a catheter to be threaded to target a vein or artery, which can be repositioned and released, into a final state. Unlike vascular plug the material, a self-expandable nonmagnetic Nitinol-wire allows for patients the ability to use a magnetic resonance imager (MRI) technology (Journal of Cardiovascular Management, 2004). The plug devices benefit pediatric and geriatric patients with the ability for the device to expand and shape to the
…show more content…
In the Netherlands the litigation at first obtained an appeal in favor or Occlutech and then overturned in 2010 in favor for AGA Medical. The litigation pending for the company has continued for years with product lines forming new technology and launch new occlude medical device into the market. Along with the litigation occurring in courtrooms in Europe, AGA Medical had issues with patent infringement in the US courts. In 2014, AGA Medical entered into litigation with the medical device company, W.L. Gore & Associates Inc., for patent infringement for a heart defect treatment device. The litigation was intended for the company to protect the technology and the intellectual property of the company. Gore & Associates was found to not be infringing on the patent co-owned by St Jude Medical and AGA …show more content…
The acquisition allowed for the market to be opened to left atrial appendage closure and foramen ovale closure which benefits abnormal peripheral vessels with vascular plugs and repair structural hear defects. The revenue expecting to be generated by AGA Medical acquisition would contribute to St Jude Medical would increase 19 percent revenue growth (Reuters, 2015). The revenue was expected to generate low double-digits revenue and benefit future products technology growth of the company. The results of the first quarter post acquisition demonstrated the company revenue increasing by 9 percent with revenue for the company being $1.38 billion in the first quarter alone. The acquisition of AGA Medical was an expensive acquisition with the incorporation of the debt and the termination of international contracts. The sales of cardiovascular sales increase by 28 percent from 2010 to 2011 with the majority of profits coming from AGA Medical product lines. The CEO of St Jude Medical was encouraged by the 2010 US sales that would benefit the company with continuous expected organic growth of 10 percent with a constant currency basis. The 2011 annual report to shareholder published by St Jude Medical demonstrated the impact of the benefit of the acquisition of AGA Medical. The net sales for the
In the Netherlands the litigation at first obtained an appeal in favor or Occlutech and then overturned in 2010 in favor for AGA Medical. The litigation pending for the company has continued for years with product lines forming new technology and launch new occlude medical device into the market. Along with the litigation occurring in courtrooms in Europe, AGA Medical had issues with patent infringement in the US courts. In 2014, AGA Medical entered into litigation with the medical device company, W.L. Gore & Associates Inc., for patent infringement for a heart defect treatment device. The litigation was intended for the company to protect the technology and the intellectual property of the company. Gore & Associates was found to not be infringing on the patent co-owned by St Jude Medical and AGA …show more content…
The acquisition allowed for the market to be opened to left atrial appendage closure and foramen ovale closure which benefits abnormal peripheral vessels with vascular plugs and repair structural hear defects. The revenue expecting to be generated by AGA Medical acquisition would contribute to St Jude Medical would increase 19 percent revenue growth (Reuters, 2015). The revenue was expected to generate low double-digits revenue and benefit future products technology growth of the company. The results of the first quarter post acquisition demonstrated the company revenue increasing by 9 percent with revenue for the company being $1.38 billion in the first quarter alone. The acquisition of AGA Medical was an expensive acquisition with the incorporation of the debt and the termination of international contracts. The sales of cardiovascular sales increase by 28 percent from 2010 to 2011 with the majority of profits coming from AGA Medical product lines. The CEO of St Jude Medical was encouraged by the 2010 US sales that would benefit the company with continuous expected organic growth of 10 percent with a constant currency basis. The 2011 annual report to shareholder published by St Jude Medical demonstrated the impact of the benefit of the acquisition of AGA Medical. The net sales for the